



NEWS FOR IMMEDIATE RELEASE

Contact Information:

Adrienne Choma
President & COO
Saladax Biomedical, Inc.
(201) 240-4072
achoma@saladax.com

SALADAX BIOMEDICAL ANNOUNCES DISTRIBUTION AGREEMENT FOR PERSONALIZED CHEMOTHERAPY MANAGEMENT (PCM®) KITS

Bethlehem, PA, May 27, 2009 -- Saladax Biomedical, Inc. (www.saladax.com), a personalized medicine diagnostics company pioneering the development of Personalized Chemotherapy Management (PCM®) assays to test blood levels of the most commonly used anti-cancer medicines, has signed an agreement with Lab21 for supply of testing services in the United Kingdom, Ireland and the Middle East.

Lab21 is a global provider of state-of-the-art diagnostic products and will be the first clinical reference lab to provide testing services based upon the novel Saladax 5-Fluorouracil (5-FU) PCM reagent kits. 5-FU is the foundation for colorectal cancer infusion chemotherapy regimens, and is also used for treating head and neck and metastatic breast cancer. The 5-FU assay is just one of a portfolio of PCM assays developed, or under development, by Saladax.

Studies have demonstrated that when chemotherapy drug levels are optimized, treatment can be more efficient and effective, and patients suffer fewer side effects. However, until now oncologists have not had a convenient way of measuring plasma levels, which can vary among individuals as much as 30-fold. As a result, many patients are either over-dosed or under-dosed.

Berwyn Clarke, Chief Scientific and Development Officer of Lab21, said, "We are very pleased to be the first to bring this important development in the treatment of cancer to our physician base. It will provide higher physician confidence in dosing this widely used drug and will provide patients with the potential of longer survival with a better quality of life while undergoing treatment." Lab21 (www.lab21.com) will market the dose management service under the trade name *DoseCheck*™.

In the May 2008 issue of the *Journal of Clinical Oncology*, Dr. Erick Gamelin at the Paul Papin Cancer Center in Angers, France reported a randomized multi-center study among metastatic colorectal cancer patients treated with continuous infusion 5-FU whose drug blood levels were monitored and dosing adjusted to achieve target concentrations. Dr. Gamelin demonstrated that dosing based on BSA resulted in 68% of patients having sub-therapeutic plasma levels; 17% of patients were over-dosed and only 15% were actually in the optimal therapeutic range. When 5-

FU dosing was optimized to the target blood levels, objective response rates nearly doubled, with a trend towards a six month improvement in median overall survival. At the same time the most severe toxicities were nearly eliminated.

“We are pleased to be expanding the availability of our 5-FU PCM[®] Assay to the markets served by Lab21. Our objective is to make this unique new tool available to oncologists around the world for the improvement of cancer patient care,” said Dr. Sal Salamone, CEO of Saladax Biomedical.

About Saladax Biomedical, Inc.

Saladax Biomedical, Inc. is a personalized diagnostics company with its main R&D and manufacturing facilities based in Bethlehem, PA. Founded in 2004, Saladax is pioneering the development of an innovative line of proprietary Personalized Chemotherapy Management (PCM[®]) assays to test plasma levels of the most commonly used anti-cancer medicines. In the European Union, Saladax is marketing its 5-FU PCM Assay directly and has obtained a CE Mark for product distribution.

For more information about Saladax, visit www.saladax.com.

About Lab21 Limited

Lab21 is a global provider of state-of-the-art diagnostic products and services, supporting blood bank screening, medical diagnostics and drug discovery. Its customers include international healthcare providers, pharmaceutical and biotechnology companies.

The product division of the Company manufactures immunodiagnostic kits and reagents that are distributed into 110 countries and is focused on infectious diseases for the blood-banking market. The service division has a growing test portfolio providing companion diagnostics and high technology molecular assays for the growing integration of personalised medicine into healthcare. These services are currently in infectious diseases, oncology and pharmacogenetics areas with emerging interests in cardiovascular and metabolic disease.

Lab21's clinical reference laboratory and corporate office is based in Cambridge and has additional UK manufacturing sites in Newmarket and Ipswich. It also has R&D operations in Cape Town, South Africa. The Company's investors include Merlin Biosciences, Nexus Medical Partners, Medicis Ventures, Rowan Dartington and Kreos Capital.

Website: www.lab21.com

#